Performance Claims & Clinical Benefits
This page displays the performance claims validated through clinical studies and the intended clinical benefits derived from these claims.
Performance Claims
Performance claims represent specific acceptance criteria tested in clinical validation studies, showing how the device meets performance thresholds.
Filters
| ID | Study | Device | Domain | Indications | User Group | Metric | Value Achieved | Threshold | Global Value | State of Art | Achieved | vs SOTA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LL5 | AIHS4 2025 | Plus | Objective severity assessment | Hidradenitis supurativa | Dermatologists | inter-observer intraclass correlation coefficient (ICC) | 72.70% | 70.00% Equal to or greater than | 72.70% | 47.00% | Achieved | Exceeds SOTA |
| SDP | AIHS4 2025 | Plus | Objective severity assessment | Hidradenitis supurativa | Dermatologists | inter-class coefficient correlation variability (ICC) | 10.00% | 15.00% Lower than | 10.00% | 10.00% | Achieved | Below SOTA |
| MRT | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners, Dermatologists | top-1 accuracy | 15.12% | 7.00% Equal to or greater than | 15.43% | 6.36% | Achieved | Exceeds SOTA |
| 9D7 | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners, Dermatologists | top-1 accuracy | 63.06% | 47.94% Greater than | 71.21% | NaN% | Achieved | Below SOTA |
| ZKC | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners, Dermatologists | top-1 accuracy | 63.06% | 53.96% Equal to or greater than | 71.21% | 49.05% | Achieved | Exceeds SOTA |
| 02A | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners, Dermatologists | sensitivity | 18.43% | 6.93% Greater than | 18.73% | 6.30% | Achieved | Exceeds SOTA |
| 5IT | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners, Dermatologists | sensitivity | 71.04% | 70.00% Greater than | 73.53% | 69.08% | Achieved | Exceeds SOTA |
| ASM | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners, Dermatologists | sensitivity | 71.04% | 52.61% Greater than | 73.53% | NaN% | Achieved | Below SOTA |
| X70 | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners, Dermatologists | specificity | 19.38% | 5.06% Equal to or greater than | 18.91% | 4.60% | Achieved | Exceeds SOTA |
| 0ZD | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners, Dermatologists | specificity | 75.83% | 70.00% Equal to or greater than | 78.20% | 76.47% | Achieved | Below SOTA |
| MJY | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners, Dermatologists | specificity | 75.83% | 56.45% Greater than | 78.20% | NaN% | Achieved | Below SOTA |
| O4L | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | top-1 accuracy | 17.00% | 7.00% Equal to or greater than | 17.89% | 6.36% | Achieved | Exceeds SOTA |
| GZS | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | top-1 accuracy | 61.71% | 47.91% Equal to or greater than | 70.73% | NaN% | Achieved | Below SOTA |
| 31Q | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | top-1 accuracy | 61.71% | 46.12% Equal to or greater than | 70.73% | 41.93% | Achieved | Exceeds SOTA |
| 81T | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | sensitivity | 18.43% | 14.30% Equal to or greater than | 18.90% | 13.00% | Achieved | Exceeds SOTA |
| 37G | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | sensitivity | 71.04% | 66.30% Equal to or greater than | 74.33% | 66.30% | Achieved | Exceeds SOTA |
| 19H | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | sensitivity | 71.04% | 52.61% Greater than | 74.33% | NaN% | Achieved | Below SOTA |
| 0H6 | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | specificity | 19.38% | 11.88% Equal to or greater than | 19.87% | 10.80% | Achieved | Exceeds SOTA |
| H3D | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | specificity | 75.83% | 70.10% Equal to or greater than | 80.00% | 70.10% | Achieved | Exceeds SOTA |
| 0QF | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | specificity | 75.83% | 56.45% Greater than | 80.00% | NaN% | Achieved | Below SOTA |
| 6FT | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | top-1 accuracy | 8.30% | 5.83% Equal to or greater than | 9.02% | 5.30% | Achieved | Exceeds SOTA |
| GU0 | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | top-1 accuracy | 65.65% | 57.25% Equal to or greater than | 72.52% | NaN% | Achieved | Below SOTA |
| 47J | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | top-1 accuracy | 65.65% | 61.80% Equal to or greater than | 72.52% | 56.18% | Achieved | Exceeds SOTA |
| W8N | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | sensitivity | 9.37% | 6.93% Equal to or greater than | 10.57% | 6.30% | Achieved | Exceeds SOTA |
| A76 | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | sensitivity | 71.01% | 70.00% Equal to or greater than | 75.27% | 72.86% | Achieved | Below SOTA |
| CUC | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | sensitivity | 71.01% | 61.64% Greater than | 75.27% | NaN% | Achieved | Below SOTA |
| R9C | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | specificity | 10.61% | 5.06% Equal to or greater than | 10.11% | 4.60% | Achieved | Exceeds SOTA |
| 9MI | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | specificity | 73.08% | 77.60% Equal to or greater than | 81.95% | 77.60% | Not Achieved | Below SOTA |
| NLW | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | specificity | 73.08% | 62.47% Greater than | 81.95% | NaN% | Achieved | Below SOTA |
| DII | BI_2024 | Plus | Diagnostic accuracy | Rare diseases | Primary care practitioners, Dermatologists | top-1 accuracy | 26.77% | 6.93% Equal to or greater than | 26.02% | 6.30% | Achieved | Exceeds SOTA |
| KOQ | BI_2024 | Plus | Diagnostic accuracy | Rare diseases | Primary care practitioners, Dermatologists | top-1 accuracy | 57.88% | 30.90% Equal to or greater than | 53.68% | NaN% | Achieved | Below SOTA |
| NK7 | BI_2024 | Plus | Diagnostic accuracy | Rare diseases | Primary care practitioners, Dermatologists | sensitivity | 25.56% | 6.93% Equal to or greater than | 21.25% | 6.30% | Achieved | Exceeds SOTA |
| DR7 | BI_2024 | Plus | Diagnostic accuracy | Rare diseases | Primary care practitioners, Dermatologists | sensitivity | 46.59% | 21.04% Greater than | 41.45% | NaN% | Achieved | Below SOTA |
| 0I1 | BI_2024 | Plus | Diagnostic accuracy | Rare diseases | Primary care practitioners, Dermatologists | specificity | 23.50% | 5.06% Equal to or greater than | 21.59% | 4.60% | Achieved | Exceeds SOTA |
| WAM | BI_2024 | Plus | Diagnostic accuracy | Rare diseases | Primary care practitioners, Dermatologists | specificity | 62.19% | 38.69% Greater than | 59.88% | NaN% | Achieved | Below SOTA |
| JBB | BI_2024 | Plus | Diagnostic accuracy | Rare diseases | Primary care practitioners | top-1 accuracy | 32.10% | 6.93% Equal to or greater than | 30.58% | 6.30% | Achieved | Exceeds SOTA |
| ERK | BI_2024 | Plus | Diagnostic accuracy | Rare diseases | Primary care practitioners | top-1 accuracy | 56.44% | 24.34% Equal to or greater than | 52.41% | NaN% | Achieved | Below SOTA |
| 8PG | BI_2024 | Plus | Diagnostic accuracy | Rare diseases | Primary care practitioners | sensitivity | 25.21% | 14.30% Equal to or greater than | 25.04% | 13.00% | Achieved | Exceeds SOTA |
| DIK | BI_2024 | Plus | Diagnostic accuracy | Rare diseases | Primary care practitioners | sensitivity | 44.55% | 19.33% Greater than | 44.55% | NaN% | Achieved | Below SOTA |
| 99Y | BI_2024 | Plus | Diagnostic accuracy | Rare diseases | Primary care practitioners | specificity | 24.73% | 11.88% Equal to or greater than | 23.50% | 10.80% | Achieved | Exceeds SOTA |
| 8QZ | BI_2024 | Plus | Diagnostic accuracy | Rare diseases | Primary care practitioners | specificity | 61.36% | 36.64% Greater than | 62.19% | NaN% | Achieved | Below SOTA |
| 4KO | BI_2024 | Plus | Diagnostic accuracy | Rare diseases | Dermatologists | top-1 accuracy | 12.97% | 5.83% Equal to or greater than | 12.97% | 5.30% | Achieved | Exceeds SOTA |
| S03 | BI_2024 | Plus | Diagnostic accuracy | Rare diseases | Dermatologists | top-1 accuracy | 61.11% | 48.15% Equal to or greater than | 61.11% | NaN% | Achieved | Below SOTA |
| TG6 | BI_2024 | Plus | Diagnostic accuracy | Rare diseases | Dermatologists | sensitivity | 16.44% | 6.93% Equal to or greater than | 16.44% | 6.30% | Achieved | Exceeds SOTA |
| OR5 | BI_2024 | Plus | Diagnostic accuracy | Rare diseases | Dermatologists | sensitivity | 52.33% | 35.89% Greater than | 52.33% | NaN% | Achieved | Below SOTA |
| Q2D | BI_2024 | Plus | Diagnostic accuracy | Rare diseases | Dermatologists | specificity | 15.41% | 5.06% Equal to or greater than | 15.41% | 4.60% | Achieved | Exceeds SOTA |
| MM8 | BI_2024 | Plus | Diagnostic accuracy | Rare diseases | Dermatologists | specificity | 71.08% | 55.67% Greater than | 71.08% | NaN% | Achieved | Below SOTA |
| 3OA | COVIDX_EVCDAO_2022 | Plus | Delphi-based consensus | Multiple conditions | Dermatologists | (CUS) | 80.00% | 75.00% Equal to or greater than | 80.00% | 75.00% | Achieved | Exceeds SOTA |
| ZGP | COVIDX_EVCDAO_2022 | Plus | Delphi-based consensus | Multiple conditions | Dermatologists | 50.00% | 75.00% Between range | 79.60% | 75.00% | Not Achieved | Below SOTA | |
| RND | COVIDX_EVCDAO_2022 | Plus | Delphi-based consensus | Multiple conditions | Dermatologists | 100.00% | 75.00% Equal to or greater than | 100.00% | 75.00% | Achieved | Exceeds SOTA | |
| P30 | COVIDX_EVCDAO_2022 | Plus | Delphi-based consensus | Multiple conditions | Dermatologists | 100.00% | 75.00% Equal to or greater than | 100.00% | 75.00% | Achieved | Exceeds SOTA | |
| EZ1 | COVIDX_EVCDAO_2022 | Plus | Delphi-based consensus | Multiple conditions | Dermatologists | 83.00% | 75.00% Equal to or greater than | 83.00% | 75.00% | Achieved | Exceeds SOTA | |
| 3BD | COVIDX_EVCDAO_2022 | Plus | Delphi-based consensus | Multiple conditions | Dermatologists | 67.00% | 75.00% Equal to or greater than | 67.00% | 75.00% | Not Achieved | Below SOTA | |
| NVT | COVIDX_EVCDAO_2022 | Plus | Delphi-based consensus | Multiple conditions | Dermatologists | (CUS) | 76.67% | 80.00% Equal to or greater than | 76.67% | 80.00% | Not Achieved | Below SOTA |
| EAC | DAO_Derivación_PH_2022 | Plus | Detection | Multiple malignant conditions | Dermatologists | area under the ROC curve (AUC) | 84.20% | 80.00% Equal to or greater than | 91.00% | 77.80% | Achieved | Exceeds SOTA |
| 8H5 | DAO_Derivación_PH_2022 | Plus | Resource optimisation | Multiple conditions | Dermatologists | increase in the adequacy of referrals | 7.00% | 15.00% Equal to or greater than | 38.00% | 24.00% | Not Achieved | Below SOTA |
| VCT | DAO_Derivación_PH_2022 | Plus | Delphi-based consensus | Multiple conditions | Dermatologists | 80.00% | 70.00% Equal to or greater than | 80.00% | 70.00% | Achieved | Exceeds SOTA | |
| DX7 | DAO_Derivation_O_2022 | Plus | Detection | Multiple malignant conditions | Primary care practitioners | area under the ROC curve (AUC) | 82.00% | 80.00% Equal to or greater than | 91.00% | 77.80% | Achieved | Exceeds SOTA |
| LU4 | DAO_Derivation_O_2022 | Plus | Detection | Multiple malignant conditions | Primary care practitioners | sensitivity | 57.14% | 80.00% Equal to or greater than | 79.10% | 78.40% | Not Achieved | Below SOTA |
| R9P | DAO_Derivation_O_2022 | Plus | Detection | Multiple malignant conditions | Primary care practitioners | specificity | 93.53% | 84.00% Equal to or greater than | 87.30% | 84.00% | Achieved | Exceeds SOTA |
| 0L2 | DAO_Derivation_O_2022 | Plus | Detection | Multiple malignant conditions | Primary care practitioners | positive predictive value (PPV) | 42.00% | 40.00% Equal to or greater than | 42.00% | N/A | Achieved | N/A |
| 7ZI | DAO_Derivation_O_2022 | Plus | Detection | Multiple malignant conditions | Primary care practitioners | negative predictive value (NPV) | 96.00% | 80.00% Equal to or greater than | 96.00% | N/A | Achieved | N/A |
| D62 | DAO_Derivation_O_2022 | Plus | Adequacy of referrals | Multiple conditions | Primary care practitioners | adequacy of referrals | 38.00% | 15.00% Equal to or greater than | 38.00% | 14.00% | Achieved | Exceeds SOTA |
| CST | DAO_Derivation_O_2022 | Plus | Adequacy of referrals | Multiple conditions | Primary care practitioners | sensitivity | 74.00% | 72.93% Equal to or greater than | 74.20% | 66.30% | Achieved | Exceeds SOTA |
| 6H0 | DAO_Derivation_O_2022 | Plus | Adequacy of referrals | Multiple conditions | Primary care practitioners | sensitivity | 74.00% | 45.00% Equal to or greater than | 74.20% | NaN% | Achieved | Below SOTA |
| H4U | DAO_Derivation_O_2022 | Plus | Adequacy of referrals | Multiple conditions | Primary care practitioners | specificity | 67.00% | 66.11% Equal to or greater than | 67.30% | 60.10% | Achieved | Exceeds SOTA |
| 04D | DAO_Derivation_O_2022 | Plus | Adequacy of referrals | Multiple conditions | Primary care practitioners | specificity | 67.00% | 47.00% Equal to or greater than | 67.30% | NaN% | Achieved | Below SOTA |
| DCH | DAO_Derivation_O_2022 | Plus | Adequacy of referrals | Multiple conditions | Primary care practitioners | adequacy of referrals during in-person care | 78.60% | 50.00% Equal to or greater than | 74.20% | NaN% | Achieved | Below SOTA |
| DZC | DAO_Derivation_O_2022 | Plus | Adequacy of referrals | Multiple conditions | Primary care practitioners | adequacy of referrals during in-person care | 67.60% | 38.90% Equal to or greater than | 67.30% | NaN% | Achieved | Below SOTA |
| LHF | DAO_Derivation_O_2022 | Plus | Adequacy of referrals | Multiple conditions | Primary care practitioners | adequacy of referrals during remote care | 33.00% | 0.00% Equal to or greater than | 33.00% | NaN% | Achieved | Below SOTA |
| 4BO | DAO_Derivation_O_2022 | Plus | Adequacy of referrals | Multiple conditions | Primary care practitioners | adequacy of referrals during remote care | 67.00% | 67.00% Equal to or greater than | 67.00% | NaN% | Achieved | Below SOTA |
| KPQ | DAO_Derivation_O_2022 | Plus | Resource optimisation | Multiple conditions | Primary care practitioners | reduction in the number of days | 84.37% | 78.10% Greater than | 84.37% | 71.00% | Achieved | Exceeds SOTA |
| 1M1 | DAO_Derivation_O_2022 | Plus | Resource optimisation | Multiple conditions | Primary care practitioners | reduction in the number of days | 56.00% | 30.00% Equal to or greater than | 56.00% | 71.00% | Achieved | Below SOTA |
| UGS | DAO_Derivation_O_2022 | Plus | Resource optimisation | Multiple conditions | Primary care practitioners | reduction in the number of days | 5 days | 10.35 Lower than | 500.00% | 11.5 | Achieved | Exceeds SOTA |
| LXJ | IDEI_2023 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | top-1 accuracy | 82.14% | 61.80% Equal to or greater than | 72.52% | 56.18% | Achieved | Exceeds SOTA |
| KW3 | IDEI_2023 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | top-1 accuracy | 78.57% | 50.00% Equal to or greater than | 61.95% | 50.70% | Achieved | Exceeds SOTA |
| 7V9 | IDEI_2023 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | top-3 accuracy | 89.29% | 60.00% Equal to or greater than | 79.81% | 64.00% | Achieved | Exceeds SOTA |
| 1S5 | IDEI_2023 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | top-5 accuracy | 89.29% | 80.00% Equal to or greater than | 86.40% | 80.00% | Achieved | Exceeds SOTA |
| FIQ | IDEI_2023 | Plus | Detection | Multiple malignant conditions | Dermatologists | area under the ROC curve (AUC) | 97.00% | 80.00% Equal to or greater than | 91.00% | 77.80% | Achieved | Exceeds SOTA |
| GS5 | IDEI_2023 | Plus | Detection | Multiple malignant conditions | Dermatologists | sensitivity | 87.50% | 80.00% Equal to or greater than | 79.10% | 78.40% | Achieved | Exceeds SOTA |
| 6EP | IDEI_2023 | Plus | Detection | Multiple malignant conditions | Dermatologists | specificity | 97.06% | 84.00% Equal to or greater than | 87.30% | 84.00% | Achieved | Exceeds SOTA |
| PZD | IDEI_2023 | Plus | Detection | Multiple malignant conditions | Dermatologists | positive predictive value (PPV) | 87.50% | 80.00% Equal to or greater than | 89.00% | N/A | Achieved | N/A |
| V2U | IDEI_2023 | Plus | Detection | Multiple malignant conditions | Dermatologists | negative positive value (NPV) | 97.06% | 95.00% Equal to or greater than | 82.50% | N/A | Achieved | N/A |
| JWQ | IDEI_2023 | Plus | Objective severity assessment | Androgenetic alopecia | Dermatologists | correlation | 77.00% | 50.00% Equal to or greater than | 65.00% | 60.00% | Achieved | Exceeds SOTA |
| A1Q | IDEI_2023 | Plus | Objective severity assessment | Androgenetic alopecia | Dermatologists | unweighted Kappa | 73.97% | 60.00% Equal to or greater than | 62.35% | 60.00% | Achieved | Exceeds SOTA |
| 284 | IDEI_2023 | Plus | Objective severity assessment | Androgenetic alopecia | Dermatologists | correlation | 47.00% | 50.00% Equal to or greater than | 65.00% | 60.00% | Not Achieved | Below SOTA |
| 3OB | IDEI_2023 | Plus | Objective severity assessment | Androgenetic alopecia | Dermatologists | unweighted Kappa | 32.97% | 60.00% Equal to or greater than | 62.35% | 60.00% | Not Achieved | Below SOTA |
| 7TS | IDEI_2023 | Plus | Objective severity assessment | Androgenetic alopecia | Dermatologists | correlation | 53.00% | 50.00% Equal to or greater than | N/A | N/A | Achieved | N/A |
| WGP | MC_EVCDAO_2019 | Legacy | Diagnostic accuracy | Multiple conditions | Dermatologists | top-1 accuracy | 55.00% | 50.00% Equal to or greater than | 61.95% | 50.70% | Achieved | Exceeds SOTA |
| 6R7 | MC_EVCDAO_2019 | Legacy | Diagnostic accuracy | Multiple conditions | Dermatologists | top-3 accuracy | 75.84% | 60.00% Equal to or greater than | 79.81% | 64.00% | Achieved | Exceeds SOTA |
| EYP | MC_EVCDAO_2019 | Legacy | Diagnostic accuracy | Multiple conditions | Dermatologists | top-5 accuracy | 84.22% | 80.00% Equal to or greater than | 86.40% | 80.00% | Achieved | Exceeds SOTA |
| 6U1 | MC_EVCDAO_2019 | Legacy | Detection | Melanoma | Dermatologists | area under the ROC curve (AUC) | 85.00% | 80.00% Equal to or greater than | 85.00% | 81.00% | Achieved | Exceeds SOTA |
| JFM | MC_EVCDAO_2019 | Legacy | Detection | Melanoma | Dermatologists | top-1 accuracy | 81.00% | 80.00% Equal to or greater than | 81.00% | 75.40% | Achieved | Exceeds SOTA |
| ZM8 | MC_EVCDAO_2019 | Legacy | Detection | Melanoma | Dermatologists | sensitivity | 93.00% | 80.00% Equal to or greater than | 93.00% | 73.40% | Achieved | Exceeds SOTA |
| 4JY | MC_EVCDAO_2019 | Legacy | Detection | Melanoma | Dermatologists | specificity | 80.00% | 70.00% Equal to or greater than | 80.00% | 76.20% | Achieved | Exceeds SOTA |
| 9OD | MC_EVCDAO_2019 | Legacy | Detection | Multiple malignant conditions | Dermatologists | area under the ROC curve (AUC) | 89.83% | 80.00% Equal to or greater than | 91.00% | 77.80% | Achieved | Exceeds SOTA |
| BRI | MC_EVCDAO_2019 | Legacy | Detection | Multiple malignant conditions | Dermatologists | sensitivity | 81.00% | 80.00% Equal to or greater than | 79.10% | 78.40% | Achieved | Exceeds SOTA |
| VFY | MC_EVCDAO_2019 | Legacy | Detection | Multiple malignant conditions | Dermatologists | specificity | 86.00% | 84.00% Equal to or greater than | 87.30% | 84.00% | Achieved | Exceeds SOTA |
| 9G4 | MC_EVCDAO_2019 | Legacy | Detection | Multiple malignant conditions | Dermatologists | positive predictive value (PPV) | 92.47% | 80.00% Equal to or greater than | 89.00% | N/A | Achieved | N/A |
| Z96 | MC_EVCDAO_2019 | Legacy | Detection | Multiple malignant conditions | Dermatologists | negative positive value (NPV) | 67.89% | 90.00% Equal to or greater than | 82.50% | N/A | Not Achieved | N/A |
| 6KX | PH_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | top-1 accuracy | 18.15% | 7.00% Equal to or greater than | 17.89% | 6.36% | Achieved | Exceeds SOTA |
| CZR | PH_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | top-1 accuracy | 81.85% | 63.70% Equal to or greater than | 70.73% | NaN% | Achieved | Below SOTA |
| F16 | PH_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | top-1 accuracy | 81.85% | 46.12% Equal to or greater than | 70.73% | 41.93% | Achieved | Exceeds SOTA |
| 09O | PH_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | sensitivity | 14.60% | 14.30% Equal to or greater than | 18.90% | 13.00% | Achieved | Exceeds SOTA |
| HUG | PH_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | sensitivity | 83.15% | 72.93% Equal to or greater than | 74.33% | 66.30% | Achieved | Exceeds SOTA |
| JZ1 | PH_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | sensitivity | 83.15% | 68.55% Equal to or greater than | 74.33% | NaN% | Achieved | Below SOTA |
| VEF | PH_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | specificity | 11.90% | 11.88% Equal to or greater than | 19.87% | 10.80% | Achieved | Exceeds SOTA |
| QX8 | PH_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | specificity | 89.91% | 77.11% Equal to or greater than | 80.00% | 70.10% | Achieved | Exceeds SOTA |
| VCN | PH_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | specificity | 89.91% | 78.01% Equal to or greater than | 80.00% | NaN% | Achieved | Below SOTA |
| I7Y | PH_2024 | Plus | Diagnostic accuracy | Rare diseases, Pustular psoriasis | Primary care practitioners | top-1 accuracy | 16.66% | 10.00% Equal to or greater than | 30.58% | 10.00% | Achieved | Exceeds SOTA |
| Z90 | PH_2024 | Plus | Diagnostic accuracy | Rare diseases, Pustular psoriasis | Primary care practitioners | top-1 accuracy | 22.22% | 5.56% Equal to or greater than | 52.41% | NaN% | Achieved | Below SOTA |
| 6YW | PH_2024 | Plus | Diagnostic accuracy | Rare diseases, Pustular psoriasis | Primary care practitioners | sensitivity | 22.22% | 14.30% Equal to or greater than | 25.40% | 13.00% | Achieved | Exceeds SOTA |
| REV | PH_2024 | Plus | Diagnostic accuracy | Rare diseases, Pustular psoriasis | Primary care practitioners | sensitivity | 44.44% | 22.22% Greater than | 44.57% | NaN% | Achieved | Below SOTA |
| 5W2 | PH_2024 | Plus | Diagnostic accuracy | Rare diseases, Pustular psoriasis | Primary care practitioners | specificity | 51.85% | 11.88% Equal to or greater than | 23.50% | 10.80% | Achieved | Exceeds SOTA |
| CH0 | PH_2024 | Plus | Diagnostic accuracy | Rare diseases, Pustular psoriasis | Primary care practitioners | specificity | 74.07% | 22.22% Greater than | 62.19% | NaN% | Achieved | Below SOTA |
| IP4 | PH_2024 | Plus | Resource optimisation | Multiple conditions | Primary care practitioners | reduction in the number of days | 60.70% | 40.00% Equal to or greater than | 58.10% | 55.00% | Achieved | Exceeds SOTA |
| WOI | PH_2024 | Plus | Resource optimisation | Multiple conditions | Primary care practitioners | increase in patients that can be managed remotely | 49.00% | 76.00% Equal to or greater than | 33.18% | 24.00% | Not Achieved | Exceeds SOTA |
| 61I | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners, Dermatologists | top-1 accuracy | 20.00% | 7.00% Equal to or greater than | 15.43% | 6.36% | Achieved | Exceeds SOTA |
| YJC | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners, Dermatologists | top-1 accuracy | 88.78% | 53.96% Equal to or greater than | 71.21% | 49.05% | Achieved | Exceeds SOTA |
| ME3 | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners, Dermatologists | top-1 accuracy | 88.78% | 68.08% Equal to or greater than | 71.21% | NaN% | Achieved | Below SOTA |
| A84 | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners, Dermatologists | sensitivity | 28.03% | 6.93% Equal to or greater than | 18.73% | 6.30% | Achieved | Exceeds SOTA |
| 5UM | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners, Dermatologists | sensitivity | 80.64% | 75.99% Greater than | 73.53% | 69.08% | Achieved | Exceeds SOTA |
| S2C | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners, Dermatologists | sensitivity | 80.64% | 52.61% Greater than | 73.53% | NaN% | Achieved | Below SOTA |
| ZGT | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners, Dermatologists | specificity | 30.39% | 5.06% Equal to or greater than | 18.91% | 4.60% | Achieved | Exceeds SOTA |
| FEH | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners, Dermatologists | specificity | 86.84% | 84.12% Greater than | 78.20% | 76.47% | Achieved | Exceeds SOTA |
| VFV | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners, Dermatologists | specificity | 86.84% | 56.45% Greater than | 78.20% | NaN% | Achieved | Below SOTA |
| AR8 | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | top-1 accuracy | 27.00% | 7.00% Equal to or greater than | 17.89% | 6.36% | Achieved | Exceeds SOTA |
| 5XF | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | top-1 accuracy | 89.92% | 46.12% Equal to or greater than | 70.73% | 41.93% | Achieved | Exceeds SOTA |
| R7X | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | top-1 accuracy | 89.92% | 62.90% Equal to or greater than | 70.73% | NaN% | Achieved | Below SOTA |
| 7YC | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | sensitivity | 24.95% | 14.30% Equal to or greater than | 18.90% | 13.00% | Achieved | Exceeds SOTA |
| KPM | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | sensitivity | 76.53% | 72.93% Equal to or greater than | 74.33% | 66.30% | Achieved | Exceeds SOTA |
| 2W5 | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | sensitivity | 76.53% | 51.58% Greater than | 74.33% | NaN% | Achieved | Below SOTA |
| 9YX | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | specificity | 29.80% | 11.88% Equal to or greater than | 19.87% | 10.80% | Achieved | Exceeds SOTA |
| FBJ | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | specificity | 84.15% | 77.11% Equal to or greater than | 80.00% | 70.10% | Achieved | Exceeds SOTA |
| N2E | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Primary care practitioners | specificity | 84.15% | 54.35% Greater than | 80.00% | NaN% | Achieved | Below SOTA |
| O0B | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | top-1 accuracy | 10.50% | 5.00% Equal to or greater than | 9.02% | 5.00% | Achieved | Exceeds SOTA |
| 8V3 | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | top-1 accuracy | 86.93% | 61.80% Greater than | 72.52% | 56.18% | Achieved | Exceeds SOTA |
| UC7 | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | top-1 accuracy | 86.93% | 76.47% Greater than | 70.43% | NaN% | Achieved | Below SOTA |
| BHO | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | sensitivity | 14.70% | 6.93% Equal to or greater than | 10.57% | 6.30% | Achieved | Exceeds SOTA |
| Q5G | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | sensitivity | 85.08% | 82.80% Equal to or greater than | 75.27% | 72.86% | Achieved | Exceeds SOTA |
| 3GH | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | sensitivity | 85.08% | 70.38% Greater than | 75.27% | NaN% | Achieved | Below SOTA |
| N50 | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | specificity | 8.37% | 5.06% Equal to or greater than | 10.11% | 4.60% | Achieved | Exceeds SOTA |
| B4N | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | specificity | 90.72% | 85.36% Equal to or greater than | 81.95% | 77.60% | Achieved | Exceeds SOTA |
| YIO | SAN_2024 | Plus | Diagnostic accuracy | Multiple conditions | Dermatologists | specificity | 90.72% | 82.35% Greater than | 81.95% | NaN% | Achieved | Below SOTA |
| V2J | SAN_2024 | Plus | Resource optimisation | Multiple conditions | Dermatologists | reduction in the number of days | 42.00% | 76.00% Lower than | 33.18% | 24.00% | Achieved | Below SOTA |
| WL4 | SAN_2024 | Plus | Resource optimisation | Multiple conditions | Dermatologists | increase in patients that can be managed remotely | 55.11% | 40.00% Equal to or greater than | 58.10% | 55.00% | Achieved | Exceeds SOTA |
| LYP | SAN_2024 | Plus | Delphi-based consensus | Multiple conditions | Dermatologists | 87.00% | 75.00% Lower than | 87.00% | 70.00% | Not Achieved | Below SOTA | |
| 8MV | SAN_2024 | Plus | Delphi-based consensus | Multiple conditions | Dermatologists | 100.00% | 75.00% Equal to or greater than | 100.00% | 70.00% | Achieved | Exceeds SOTA |
Performance Claim Statements
The device enables better objective severity assessment of hidradenitis supurativa with a inter-observer intraclass correlation coefficient (ICC) value of 72.70% which is equal to or greater than the state of the art, based on expert assessment.
The device enables better objective severity assessment of hidradenitis supurativa with a inter-class coefficient correlation variability (ICC) value of 10.00% which is lower than the state of the art, based on expert assessment.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 15.12% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 63.06% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 63.06% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 18.43% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 71.04% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 71.04% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 19.38% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 75.83% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 75.83% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 17.00% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 61.71% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 61.71% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 18.43% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 71.04% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 71.04% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 19.38% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 75.83% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 75.83% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 8.30% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 65.65% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 65.65% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 9.37% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 71.01% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 71.01% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 10.61% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 73.08% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 73.08% which is greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a top-1 accuracy value of 26.77% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a top-1 accuracy value of 57.88% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a sensitivity value of 25.56% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a sensitivity value of 46.59% which is greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a specificity value of 23.50% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a specificity value of 62.19% which is greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a top-1 accuracy value of 32.10% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a top-1 accuracy value of 56.44% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a sensitivity value of 25.21% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a sensitivity value of 44.55% which is greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a specificity value of 24.73% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a specificity value of 61.36% which is greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a top-1 accuracy value of 12.97% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a top-1 accuracy value of 61.11% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a sensitivity value of 16.44% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a sensitivity value of 52.33% which is greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a specificity value of 15.41% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a specificity value of 71.08% which is greater than the state of the art.
The device enables better delphi-based consensus of multiple conditions with a (CUS) value of 80.00% which is equal to or greater than the state of the art.
The device enables better delphi-based consensus of multiple conditions with a value of 50.00% which is between range the state of the art.
The device enables better delphi-based consensus of multiple conditions with a value of 100.00% which is equal to or greater than the state of the art.
The device enables better delphi-based consensus of multiple conditions with a value of 100.00% which is equal to or greater than the state of the art.
The device enables better delphi-based consensus of multiple conditions with a value of 83.00% which is equal to or greater than the state of the art.
The device enables better delphi-based consensus of multiple conditions with a value of 67.00% which is equal to or greater than the state of the art.
The device enables better delphi-based consensus of multiple conditions with a (CUS) value of 76.67% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a area under the ROC curve (AUC) value of 84.20% which is equal to or greater than the state of the art.
The device enables better resource optimisation of multiple conditions with a increase in the adequacy of referrals value of 7.00% which is equal to or greater than the state of the art.
The device enables better delphi-based consensus of multiple conditions with a value of 80.00% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a area under the ROC curve (AUC) value of 82.00% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a sensitivity value of 57.14% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a specificity value of 93.53% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a positive predictive value (PPV) value of 42.00% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a negative predictive value (NPV) value of 96.00% which is equal to or greater than the state of the art.
The device enables better adequacy of referrals of multiple conditions with a adequacy of referrals value of 38.00% which is equal to or greater than the state of the art.
The device enables better adequacy of referrals of multiple conditions with a sensitivity value of 74.00% which is equal to or greater than the state of the art.
The device enables better adequacy of referrals of multiple conditions with a sensitivity value of 74.00% which is equal to or greater than the state of the art.
The device enables better adequacy of referrals of multiple conditions with a specificity value of 67.00% which is equal to or greater than the state of the art.
The device enables better adequacy of referrals of multiple conditions with a specificity value of 67.00% which is equal to or greater than the state of the art.
The device enables better adequacy of referrals of multiple conditions with a adequacy of referrals during in-person care value of 78.60% which is equal to or greater than the state of the art.
The device enables better adequacy of referrals of multiple conditions with a adequacy of referrals during in-person care value of 67.60% which is equal to or greater than the state of the art.
The device enables better adequacy of referrals of multiple conditions with a adequacy of referrals during remote care value of 33.00% which is equal to or greater than the state of the art.
The device enables better adequacy of referrals of multiple conditions with a adequacy of referrals during remote care value of 67.00% which is equal to or greater than the state of the art.
The device enables better resource optimisation of multiple conditions with a reduction in the number of days value of 84.37% which is greater than the state of the art.
The device enables better resource optimisation of multiple conditions with a reduction in the number of days value of 56.00% which is equal to or greater than the state of the art.
The device enables better resource optimisation of multiple conditions with a reduction in the number of days value of 5 days which is lower than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 82.14% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 78.57% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-3 accuracy value of 89.29% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-5 accuracy value of 89.29% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a area under the ROC curve (AUC) value of 97.00% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a sensitivity value of 87.50% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a specificity value of 97.06% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a positive predictive value (PPV) value of 87.50% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a negative positive value (NPV) value of 97.06% which is equal to or greater than the state of the art.
The device enables better objective severity assessment of androgenetic alopecia with a correlation value of 77.00% which is equal to or greater than the state of the art, based on expert assessment.
The device enables better objective severity assessment of androgenetic alopecia with a unweighted Kappa value of 73.97% which is equal to or greater than the state of the art, based on expert assessment.
The device enables better objective severity assessment of androgenetic alopecia with a correlation value of 47.00% which is equal to or greater than the state of the art, based on expert assessment.
The device enables better objective severity assessment of androgenetic alopecia with a unweighted Kappa value of 32.97% which is equal to or greater than the state of the art, based on expert assessment.
The device enables better objective severity assessment of androgenetic alopecia with a correlation value of 53.00% which is equal to or greater than the state of the art, based on expert assessment.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 55.00% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-3 accuracy value of 75.84% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-5 accuracy value of 84.22% which is equal to or greater than the state of the art.
The device enables better detection of melanoma with a area under the ROC curve (AUC) value of 85.00% which is equal to or greater than the state of the art.
The device enables better detection of melanoma with a top-1 accuracy value of 81.00% which is equal to or greater than the state of the art.
The device enables better detection of melanoma with a sensitivity value of 93.00% which is equal to or greater than the state of the art.
The device enables better detection of melanoma with a specificity value of 80.00% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a area under the ROC curve (AUC) value of 89.83% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a sensitivity value of 81.00% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a specificity value of 86.00% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a positive predictive value (PPV) value of 92.47% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a negative positive value (NPV) value of 67.89% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 18.15% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 81.85% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 81.85% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 14.60% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 83.15% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 83.15% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 11.90% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 89.91% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 89.91% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases, pustular psoriasis with a top-1 accuracy value of 16.66% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases, pustular psoriasis with a top-1 accuracy value of 22.22% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases, pustular psoriasis with a sensitivity value of 22.22% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases, pustular psoriasis with a sensitivity value of 44.44% which is greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases, pustular psoriasis with a specificity value of 51.85% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases, pustular psoriasis with a specificity value of 74.07% which is greater than the state of the art.
The device enables better resource optimisation of multiple conditions with a reduction in the number of days value of 60.70% which is equal to or greater than the state of the art.
The device enables better resource optimisation of multiple conditions with a increase in patients that can be managed remotely value of 49.00% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 20.00% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 88.78% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 88.78% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 28.03% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 80.64% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 80.64% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 30.39% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 86.84% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 86.84% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 27.00% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 89.92% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 89.92% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 24.95% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 76.53% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 76.53% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 29.80% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 84.15% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 84.15% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 10.50% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 86.93% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 86.93% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 14.70% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 85.08% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 85.08% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 8.37% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 90.72% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 90.72% which is greater than the state of the art.
The device enables better resource optimisation of multiple conditions with a reduction in the number of days value of 42.00% which is lower than the state of the art.
The device enables better resource optimisation of multiple conditions with a increase in patients that can be managed remotely value of 55.11% which is equal to or greater than the state of the art.
The device enables better delphi-based consensus of multiple conditions with a value of 87.00% which is lower than the state of the art.
The device enables better delphi-based consensus of multiple conditions with a value of 100.00% which is equal to or greater than the state of the art.
Clinical Benefits
Clinical benefits are intended outcomes derived from the device's performance characteristics. Each benefit is supported by multiple performance claims.
Intended Clinical Benefit
The device improves accuracy of HCPs during the diagnosis of dermatological conditions. This has a positive impact on patient management and outcomes related to diagnosis and monitoring of patients.
Means of Measure
top-1 accuracy, sensitivity, specificity
Estimated Magnitude of Benefit
- top-1 accuracy: 15.12% (Study: BI_2024, Indications: Multiple conditions)
- top-1 accuracy: 63.06% (Study: BI_2024, Indications: Multiple conditions)
- top-1 accuracy: 63.06% (Study: BI_2024, Indications: Multiple conditions)
- sensitivity: 18.43% (Study: BI_2024, Indications: Multiple conditions)
- sensitivity: 71.04% (Study: BI_2024, Indications: Multiple conditions)
- sensitivity: 71.04% (Study: BI_2024, Indications: Multiple conditions)
- specificity: 19.38% (Study: BI_2024, Indications: Multiple conditions)
- specificity: 75.83% (Study: BI_2024, Indications: Multiple conditions)
- specificity: 75.83% (Study: BI_2024, Indications: Multiple conditions)
- top-1 accuracy: 17.00% (Study: BI_2024, Indications: Multiple conditions)
- top-1 accuracy: 61.71% (Study: BI_2024, Indications: Multiple conditions)
- top-1 accuracy: 61.71% (Study: BI_2024, Indications: Multiple conditions)
- sensitivity: 18.43% (Study: BI_2024, Indications: Multiple conditions)
- sensitivity: 71.04% (Study: BI_2024, Indications: Multiple conditions)
- sensitivity: 71.04% (Study: BI_2024, Indications: Multiple conditions)
- specificity: 19.38% (Study: BI_2024, Indications: Multiple conditions)
- specificity: 75.83% (Study: BI_2024, Indications: Multiple conditions)
- specificity: 75.83% (Study: BI_2024, Indications: Multiple conditions)
- top-1 accuracy: 8.30% (Study: BI_2024, Indications: Multiple conditions)
- top-1 accuracy: 65.65% (Study: BI_2024, Indications: Multiple conditions)
- top-1 accuracy: 65.65% (Study: BI_2024, Indications: Multiple conditions)
- sensitivity: 9.37% (Study: BI_2024, Indications: Multiple conditions)
- sensitivity: 71.01% (Study: BI_2024, Indications: Multiple conditions)
- sensitivity: 71.01% (Study: BI_2024, Indications: Multiple conditions)
- specificity: 10.61% (Study: BI_2024, Indications: Multiple conditions)
- specificity: 73.08% (Study: BI_2024, Indications: Multiple conditions)
- specificity: 73.08% (Study: BI_2024, Indications: Multiple conditions)
- top-1 accuracy: 82.14% (Study: IDEI_2023, Indications: Multiple conditions)
- top-1 accuracy: 18.15% (Study: PH_2024, Indications: Multiple conditions)
- top-1 accuracy: 81.85% (Study: PH_2024, Indications: Multiple conditions)
- top-1 accuracy: 81.85% (Study: PH_2024, Indications: Multiple conditions)
- sensitivity: 14.60% (Study: PH_2024, Indications: Multiple conditions)
- sensitivity: 83.15% (Study: PH_2024, Indications: Multiple conditions)
- sensitivity: 83.15% (Study: PH_2024, Indications: Multiple conditions)
- specificity: 11.90% (Study: PH_2024, Indications: Multiple conditions)
- specificity: 89.91% (Study: PH_2024, Indications: Multiple conditions)
- specificity: 89.91% (Study: PH_2024, Indications: Multiple conditions)
- top-1 accuracy: 20.00% (Study: SAN_2024, Indications: Multiple conditions)
- top-1 accuracy: 88.78% (Study: SAN_2024, Indications: Multiple conditions)
- top-1 accuracy: 88.78% (Study: SAN_2024, Indications: Multiple conditions)
- sensitivity: 28.03% (Study: SAN_2024, Indications: Multiple conditions)
- sensitivity: 80.64% (Study: SAN_2024, Indications: Multiple conditions)
- sensitivity: 80.64% (Study: SAN_2024, Indications: Multiple conditions)
- specificity: 30.39% (Study: SAN_2024, Indications: Multiple conditions)
- specificity: 86.84% (Study: SAN_2024, Indications: Multiple conditions)
- specificity: 86.84% (Study: SAN_2024, Indications: Multiple conditions)
- top-1 accuracy: 27.00% (Study: SAN_2024, Indications: Multiple conditions)
- top-1 accuracy: 89.92% (Study: SAN_2024, Indications: Multiple conditions)
- top-1 accuracy: 89.92% (Study: SAN_2024, Indications: Multiple conditions)
- sensitivity: 24.95% (Study: SAN_2024, Indications: Multiple conditions)
- sensitivity: 76.53% (Study: SAN_2024, Indications: Multiple conditions)
- sensitivity: 76.53% (Study: SAN_2024, Indications: Multiple conditions)
- specificity: 29.80% (Study: SAN_2024, Indications: Multiple conditions)
- specificity: 84.15% (Study: SAN_2024, Indications: Multiple conditions)
- specificity: 84.15% (Study: SAN_2024, Indications: Multiple conditions)
- top-1 accuracy: 10.50% (Study: SAN_2024, Indications: Multiple conditions)
- top-1 accuracy: 86.93% (Study: SAN_2024, Indications: Multiple conditions)
- top-1 accuracy: 86.93% (Study: SAN_2024, Indications: Multiple conditions)
- sensitivity: 14.70% (Study: SAN_2024, Indications: Multiple conditions)
- sensitivity: 85.08% (Study: SAN_2024, Indications: Multiple conditions)
- sensitivity: 85.08% (Study: SAN_2024, Indications: Multiple conditions)
- specificity: 8.37% (Study: SAN_2024, Indications: Multiple conditions)
- specificity: 90.72% (Study: SAN_2024, Indications: Multiple conditions)
- specificity: 90.72% (Study: SAN_2024, Indications: Multiple conditions)
Associated Performance Claims
Intended Clinical Benefit
The device reduces waiting times for skin-related medical consultations by providing healthcare providers with additional relevant clinical information. This has a positive impact on patient management and outcomes related to the diagnosis and monitoring of patients.
Means of Measure
reduction in the number of days, increase in patients that can be managed remotely,
Estimated Magnitude of Benefit
- reduction in the number of days: 84.37% (Study: DAO_Derivation_O_2022, Indications: Multiple conditions)
- reduction in the number of days: 56.00% (Study: DAO_Derivation_O_2022, Indications: Multiple conditions)
- reduction in the number of days: 5 days (Study: DAO_Derivation_O_2022, Indications: Multiple conditions)
- increase in patients that can be managed remotely: 55.11% (Study: SAN_2024, Indications: Multiple conditions)
- ****: 100.00% (Study: SAN_2024, Indications: Multiple conditions)
Associated Performance Claims
Intended Clinical Benefit
The device improves the precision of HCPs during the referral. This has a positive impact on patient management, increases the adequacy of referrals and positively impacts outcomes related to diagnosis and monitoring of patients.
Means of Measure
adequacy of referrals, sensitivity, specificity, adequacy of referrals during in-person care
Estimated Magnitude of Benefit
- adequacy of referrals: 38.00% (Study: DAO_Derivation_O_2022, Indications: Multiple conditions)
- sensitivity: 74.00% (Study: DAO_Derivation_O_2022, Indications: Multiple conditions)
- sensitivity: 74.00% (Study: DAO_Derivation_O_2022, Indications: Multiple conditions)
- specificity: 67.00% (Study: DAO_Derivation_O_2022, Indications: Multiple conditions)
- specificity: 67.00% (Study: DAO_Derivation_O_2022, Indications: Multiple conditions)
- adequacy of referrals during in-person care: 78.60% (Study: DAO_Derivation_O_2022, Indications: Multiple conditions)
- adequacy of referrals during in-person care: 67.60% (Study: DAO_Derivation_O_2022, Indications: Multiple conditions)
Associated Performance Claims
Intended Clinical Benefit
The device improves accuracy of HCPs during the diagnosis of lesions suspicious for skin cancer. This has a positive impact on patient management and outcomes related to diagnosis and monitoring of patients, such as reducing the need for invasive procedures.
Means of Measure
area under the ROC curve, sensitivity, specificity, positive predictive value, negative predictive value, negative positive value
Estimated Magnitude of Benefit
- area under the ROC curve (AUC): 84.20% (Study: DAO_Derivación_PH_2022, Indications: Multiple malignant conditions)
- area under the ROC curve (AUC): 82.00% (Study: DAO_Derivation_O_2022, Indications: Multiple malignant conditions)
- sensitivity: 57.14% (Study: DAO_Derivation_O_2022, Indications: Multiple malignant conditions)
- specificity: 93.53% (Study: DAO_Derivation_O_2022, Indications: Multiple malignant conditions)
- positive predictive value (PPV): 42.00% (Study: DAO_Derivation_O_2022, Indications: Multiple malignant conditions)
- negative predictive value (NPV): 96.00% (Study: DAO_Derivation_O_2022, Indications: Multiple malignant conditions)
- area under the ROC curve (AUC): 97.00% (Study: IDEI_2023, Indications: Multiple malignant conditions)
- sensitivity: 87.50% (Study: IDEI_2023, Indications: Multiple malignant conditions)
- specificity: 97.06% (Study: IDEI_2023, Indications: Multiple malignant conditions)
- positive predictive value (PPV): 87.50% (Study: IDEI_2023, Indications: Multiple malignant conditions)
- negative positive value (NPV): 97.06% (Study: IDEI_2023, Indications: Multiple malignant conditions)
- area under the ROC curve (AUC): 85.00% (Study: MC_EVCDAO_2019, Indications: Melanoma)
- area under the ROC curve (AUC): 89.83% (Study: MC_EVCDAO_2019, Indications: Multiple malignant conditions)
- sensitivity: 81.00% (Study: MC_EVCDAO_2019, Indications: Multiple malignant conditions)
- specificity: 86.00% (Study: MC_EVCDAO_2019, Indications: Multiple malignant conditions)
- positive predictive value (PPV): 92.47% (Study: MC_EVCDAO_2019, Indications: Multiple malignant conditions)
- negative positive value (NPV): 67.89% (Study: MC_EVCDAO_2019, Indications: Multiple malignant conditions)
Associated Performance Claims
Intended Clinical Benefit
The device improves accuracy of HCPs during the diagnosis of rare diseases. This has a positive impact on patient management and outcomes related to diagnosis and monitoring of patients, especially those suffering from rare diseases.
Means of Measure
top-1 accuracy, sensitivity, specificity
Estimated Magnitude of Benefit
- top-1 accuracy: 26.77% (Study: BI_2024, Indications: Rare diseases)
- top-1 accuracy: 57.88% (Study: BI_2024, Indications: Rare diseases)
- sensitivity: 25.56% (Study: BI_2024, Indications: Rare diseases)
- sensitivity: 46.59% (Study: BI_2024, Indications: Rare diseases)
- specificity: 23.50% (Study: BI_2024, Indications: Rare diseases)
- specificity: 62.19% (Study: BI_2024, Indications: Rare diseases)
- top-1 accuracy: 32.10% (Study: BI_2024, Indications: Rare diseases)
- top-1 accuracy: 56.44% (Study: BI_2024, Indications: Rare diseases)
- sensitivity: 25.21% (Study: BI_2024, Indications: Rare diseases)
- sensitivity: 44.55% (Study: BI_2024, Indications: Rare diseases)
- specificity: 24.73% (Study: BI_2024, Indications: Rare diseases)
- specificity: 61.36% (Study: BI_2024, Indications: Rare diseases)
- top-1 accuracy: 12.97% (Study: BI_2024, Indications: Rare diseases)
- top-1 accuracy: 61.11% (Study: BI_2024, Indications: Rare diseases)
- sensitivity: 16.44% (Study: BI_2024, Indications: Rare diseases)
- sensitivity: 52.33% (Study: BI_2024, Indications: Rare diseases)
- specificity: 15.41% (Study: BI_2024, Indications: Rare diseases)
- specificity: 71.08% (Study: BI_2024, Indications: Rare diseases)
- top-1 accuracy: 16.66% (Study: PH_2024, Indications: Rare diseases, Pustular psoriasis)
- top-1 accuracy: 22.22% (Study: PH_2024, Indications: Rare diseases, Pustular psoriasis)
- sensitivity: 22.22% (Study: PH_2024, Indications: Rare diseases, Pustular psoriasis)
- sensitivity: 44.44% (Study: PH_2024, Indications: Rare diseases, Pustular psoriasis)
- specificity: 51.85% (Study: PH_2024, Indications: Rare diseases, Pustular psoriasis)
- specificity: 74.07% (Study: PH_2024, Indications: Rare diseases, Pustular psoriasis)
Associated Performance Claims
Intended Clinical Benefit
The device measures the degree of involvement of disease objectively, quantitatively, and reproducibly. This increases the precision of healthcare providers during the monitoring of patients. This has a positive impact on patient management and outcomes related to the monitoring of patients and treatment.
Means of Measure
inter-observer intraclass correlation coefficient, inter-class coefficient correlation variability, , correlation, unweighted Kappa
Estimated Magnitude of Benefit
- inter-observer intraclass correlation coefficient (ICC): 72.70% (Study: AIHS4 2025, Indications: Hidradenitis supurativa)
- inter-class coefficient correlation variability (ICC): 10.00% (Study: AIHS4 2025, Indications: Hidradenitis supurativa)
- ** (CUS)**: 80.00% (Study: COVIDX_EVCDAO_2022, Indications: Multiple conditions)
- correlation: 77.00% (Study: IDEI_2023, Indications: Androgenetic alopecia)
- unweighted Kappa: 73.97% (Study: IDEI_2023, Indications: Androgenetic alopecia)
- correlation: 47.00% (Study: IDEI_2023, Indications: Androgenetic alopecia)
- unweighted Kappa: 32.97% (Study: IDEI_2023, Indications: Androgenetic alopecia)
- correlation: 53.00% (Study: IDEI_2023, Indications: Androgenetic alopecia)
Associated Performance Claims
Intended Clinical Benefit
The device improves accuracy of HCPs during the remote diagnosis of skin conditions and the precision of HCPs during the remote referral. This has a positive impact on patient management and outcomes related to diagnosis and monitoring of patients, especially during remote care.
Means of Measure
, adequacy of referrals during remote care, increase in patients that can be managed remotely
Estimated Magnitude of Benefit
- ****: 100.00% (Study: COVIDX_EVCDAO_2022, Indications: Multiple conditions)
- adequacy of referrals during remote care: 33.00% (Study: DAO_Derivation_O_2022, Indications: Multiple conditions)
- adequacy of referrals during remote care: 67.00% (Study: DAO_Derivation_O_2022, Indications: Multiple conditions)
- increase in patients that can be managed remotely: 49.00% (Study: PH_2024, Indications: Multiple conditions)
- increase in patients that can be managed remotely: 55.11% (Study: SAN_2024, Indications: Multiple conditions)